艾格生物制药公司收到丁型肝炎治疗津贴通知

StephenW

Eiger Biopharmaceuticals receives notice of allowance for hepatitis D treatment
July 31, 2018

Eiger BioPharmaceuticals received a notice of allowance from the U.S. Patent and Trademark Office for a patent claim on ritonavir-boosted lonafarnib for the treatment of hepatitis D, according to a press release.

“This method of use patent covers a range of ritonavir-boosted lonafarnib doses and durations, including specific doses that we anticipate will appear on the first label of lonafarnib for treatment of hepatitis delta virus infection,” David Cory, president and CEO of Eiger, said in the release. “This patent allowance is especially timely as we finalize the protocol for our single, pivotal registration study, D-LIVR, which we plan to initiate later this year.”


The company’s proprietary drug lonafarnib is an oral, small molecule farnesyl transferase inhibitor currently in development for HDV therapy, which Eiger plans to combine with AbbVie’s Norvir (ritonavir) for improved treatment results.

The U.S. FDA and European Medicines Agency previously granted orphan drug designation for lonafarnib, and the FDA granted a fast track designation.

Reference: www.eigerbio.com

StephenW

艾格生物制药公司收到丁型肝炎治疗津贴通知
2018年7月31日

根据一份新闻稿，Eiger BioPharmaceuticals收到了美国专利商标局关于利托那韦增强的lonafarnib用于治疗丁型肝炎的专利申请的补贴通知。

“这种使用专利的方法涵盖了一系列利托那韦增强的lonafarnib剂量和持续时间，包括我们预计将出现在lonafarnib治疗肝炎病毒感染的第一个标签上的特定剂量，”Eiger总裁兼首席执行官David Cory说道，在发布中说。 “我们最终确定了我们计划于今年晚些时候启动的单一，关键性注册研究D-LIVR的协议，这项专利津贴特别及时。”


该公司的专利药物lonafarnib是一种口服的小分子法呢基转移酶抑制剂，目前正在开发用于HDV治疗，Eiger计划与AbbVie的Norvir（利托那韦）联合用于改善治疗效果。

美国FDA和欧洲药品管理局此前已授予lonafarnib孤儿药名称，并且FDA授予快速通道名称。

参考：www.eigerbio.com